| pubmed-article:3119151 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3119151 | lifeskim:mentions | umls-concept:C0027930 | lld:lifeskim |
| pubmed-article:3119151 | lifeskim:mentions | umls-concept:C0282151 | lld:lifeskim |
| pubmed-article:3119151 | lifeskim:mentions | umls-concept:C1880022 | lld:lifeskim |
| pubmed-article:3119151 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:3119151 | pubmed:dateCreated | 1988-1-20 | lld:pubmed |
| pubmed-article:3119151 | pubmed:abstractText | Dopamine depletion by treatment with alpha-methyl-p-tyrosine had no effect on methamphetamine-mediated increases in striatal neurotensin (NT) concentrations but significantly attenuated nigral increases; the attenuation in the nigral response was reversed by L-DOPA. Blockade of D2-receptors, with sulpiride, by itself increased striatal NT levels, while having no effect on the nigral NT system or its response to methamphetamine. In contrast, D1 blockade with SCH 23390 had no effect of its own on NT levels but significantly blocked the methamphetamine-induced actions in both the striatal and nigral NT systems. | lld:pubmed |
| pubmed-article:3119151 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3119151 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3119151 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3119151 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3119151 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3119151 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3119151 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3119151 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3119151 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3119151 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3119151 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3119151 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3119151 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3119151 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3119151 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3119151 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:3119151 | pubmed:issn | 0006-8993 | lld:pubmed |
| pubmed-article:3119151 | pubmed:author | pubmed-author:GibbJ WJW | lld:pubmed |
| pubmed-article:3119151 | pubmed:author | pubmed-author:HansonG RGR | lld:pubmed |
| pubmed-article:3119151 | pubmed:author | pubmed-author:MatsudaL ALA | lld:pubmed |
| pubmed-article:3119151 | pubmed:author | pubmed-author:MerchantK MKM | lld:pubmed |
| pubmed-article:3119151 | pubmed:author | pubmed-author:LetterA AAA | lld:pubmed |
| pubmed-article:3119151 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3119151 | pubmed:day | 29 | lld:pubmed |
| pubmed-article:3119151 | pubmed:volume | 422 | lld:pubmed |
| pubmed-article:3119151 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3119151 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3119151 | pubmed:pagination | 200-3 | lld:pubmed |
| pubmed-article:3119151 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:3119151 | pubmed:meshHeading | pubmed-meshheading:3119151-... | lld:pubmed |
| pubmed-article:3119151 | pubmed:meshHeading | pubmed-meshheading:3119151-... | lld:pubmed |
| pubmed-article:3119151 | pubmed:meshHeading | pubmed-meshheading:3119151-... | lld:pubmed |
| pubmed-article:3119151 | pubmed:meshHeading | pubmed-meshheading:3119151-... | lld:pubmed |
| pubmed-article:3119151 | pubmed:meshHeading | pubmed-meshheading:3119151-... | lld:pubmed |
| pubmed-article:3119151 | pubmed:meshHeading | pubmed-meshheading:3119151-... | lld:pubmed |
| pubmed-article:3119151 | pubmed:meshHeading | pubmed-meshheading:3119151-... | lld:pubmed |
| pubmed-article:3119151 | pubmed:meshHeading | pubmed-meshheading:3119151-... | lld:pubmed |
| pubmed-article:3119151 | pubmed:meshHeading | pubmed-meshheading:3119151-... | lld:pubmed |
| pubmed-article:3119151 | pubmed:meshHeading | pubmed-meshheading:3119151-... | lld:pubmed |
| pubmed-article:3119151 | pubmed:meshHeading | pubmed-meshheading:3119151-... | lld:pubmed |
| pubmed-article:3119151 | pubmed:meshHeading | pubmed-meshheading:3119151-... | lld:pubmed |
| pubmed-article:3119151 | pubmed:meshHeading | pubmed-meshheading:3119151-... | lld:pubmed |
| pubmed-article:3119151 | pubmed:meshHeading | pubmed-meshheading:3119151-... | lld:pubmed |
| pubmed-article:3119151 | pubmed:meshHeading | pubmed-meshheading:3119151-... | lld:pubmed |
| pubmed-article:3119151 | pubmed:year | 1987 | lld:pubmed |
| pubmed-article:3119151 | pubmed:articleTitle | Characterization of dopaminergic influence on striatal-nigral neurotensin systems. | lld:pubmed |
| pubmed-article:3119151 | pubmed:affiliation | Department of Pharmacology and Toxicology, University of Utah, Salt Lake City 84112. | lld:pubmed |
| pubmed-article:3119151 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3119151 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:3119151 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
